Sfoglia per RIVISTA
HAEMATOLOGICA
Collezione AO Cuneo

  

Items : 10

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. in Haematologica / Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.

2021
AO Cuneo

Vitale A; Cattaneo C; Mattei D; Fracchiolla N; Cerrano M; Cairoli R; Candoni A; Papayannidis C; De Fabritiis P; Di Raimondo F; Capria S; Apicella V; Spinelli O; Santoro A; Pierini V; Puzzolo MC; Lauretti A; Canichella M; La Starza R; Albertini Petroni G; Elia L; Ansuinelli M; Taherinasab A; Cavalli M; Cafforio L; Piciocchi A; Della Starza I; Messina M; Chiaretti S; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. in Haematologica / Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.

2019
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Santini V; Levis A; Musto P; Tassara R; Finelli C; Saglio G; Bonferroni M; Allione B; Balleari E; Poloni A; Cametti G; Ferrero D; Sanna A; Ceccarelli M; Salvi F; Danise P; Masiera E; Castiglione A; Gioia D; Messa E; Messa E; Gioia D; Masiera E; Castiglione A; Ceccarelli M; Salvi F; Danise P; Sanna A; Allione B; et alii...

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. in Haematologica / Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

2017
AO Cuneo

Bacigalupo A; Milone G; Cupri A; Severino A; Fagioli F; Berger M; Santarone S; Chiusolo P; Sica S; Mammoliti S; Sorasio R; Massi D; Van Lint MT; Raiola AM; Gualandi F; Selleri C; Sormani MP; Signori A; Risitano A; Bonifazi F;

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. in Haematologica / Haematologica. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24.

2016
AO Cuneo

Federico M; Luminari S; Pellegrini C; Merli F; Pesce EA; Chauvie S; Gandolfi L; Capodanno I; Salati M; Argnani L; Zinzani PL;

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. in Haematologica / Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.

2014
AO Cuneo

Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M;

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. in Haematologica / Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

2014
AO Cuneo

Gallamini A; Barrington SF; Biggi A; Chauvie S; Kostakoglu L; Gregianin M; Meignan M; Mikhaeel GN; Loft A; Zaucha JM; Seymour JF; Hofman MS; Rigacci L; Pulsoni A; Coleman M; Dann EJ; Trentin L; Casasnovas O; Rusconi C; Brice P; Bolis S; Viviani S; Salvi F; Luminari S; Hutchings M;

Imatinib and ruxolitinib association: first experience in two patients. in Haematologica / Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.

2014
AO Cuneo

Iurlo A; Gianelli U; Rapezzi D; Cattaneo D; Fermo E; Binda F; Santambrogio E; Bucelli C; Cortelezzi A;

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. in Haematologica / Haematologica. 2006 Apr;91(4):475-81.

2006
AO Cuneo

Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A;